Tai-Tsung Biotech Board Resolves to Waive Subscription Rights in Cash Increase of Subsidiary Taiwan Gene Nucleic Acid New Drug Co., Ltd.

1. Date of Event: July 2, 115 2. Company Name: Tai-Tsung Biotechnology Co., Ltd. 3. Relationship to Company (Please specify '本公司' or 'Subsidiary'):本公司 (Parent Company) 4. Cross-shareholding Ratio: Not applicable 5. Reason for Occurrence: To support the operational development of its subsidiary, Taiwan Gene Nucleic Acid New Drug Co., Ltd. (non-core subsidiary, abbreviated as TGNA), including attracting and retaining professional talent, integrating external resources, and introducing strategic investors to enhance operational performance and strengthen competitiveness, the Company has resolved to waive its subscription rights in this cash capital increase. 6. Countermeasures: The Chairman of TGNA, authorized by its Board of Directors, will negotiate with designated investors for subscription. 7. Other Matters to be Disclosed: This matter qualifies as material information under securities regulations, meeting the criteria under Article 7, Paragraph 9, Item 9 of the Enforcement Rules of the Securities and Exchange Act, as it may significantly affect shareholder equity or securities prices. However, the impact on the Company's shareholder equity and financial/business operations is not material.